Literature DB >> 9809028

Molecular and biological features of two new human squamous and adenocarcinoma of the lung cell lines.

A Gasperi-Campani1, L Roncuzzi, L Ricotti, L Lenzi, R Gruppioni, A Sensi, N Zini, W Zoli, D Amadori.   

Abstract

Two human cancer cell lines were established from metastatic lesions of an adenocarcinoma (RAL) and a squamous cell (CAEP) carcinoma of the lung. The clinical histories of the patients from whom the cell lines were derived are reported. The lines were maintained in continuous culture with doubling times of 65 (RAL) and 50 (CAEP) hours. The RAL and CAEP cell lines, whose morphology and ultrastructural features are presented, showed extensively rearranged karyotypes with modal number of 85 (RAL) and 98 (CAEP). In particular, chromosome 2 pentasomy and several clonal markers were evident in the RAL cells, whereas a telomeric deletion of chromosome 1, del (1)(q32), was observed in the CAEP cells. The morphologic data were confirmed by high expression of specific antigens for each histotype. A marked positivity of the neuron-specific enolase (NSE) levels was evident by immunoenzymatic assays in the cell lines cytosol with respect to those present in the respective patient's sera. No amplification or rearrangements were evident in the CMYC, LMYC, NMYC, INT-2, ERBB2, HRAS, KRAS, MOS, HST-1 genes by Southern blotting analysis in each cell line. Point mutations in exon 1 of KRAS and in exon 7 of TP53 were evident by polymerase chain reaction (PCR)-DNA sequencing in the RAL cell line, whereas no alterations were present in the HRAS and RB genes. The four genes studied did not show point mutations in the CAEP cell line. The RAL cell line was resistant to all the drugs tested, whereas the CAEP cells were sensitive to vinblastine. These cell lines may represent useful experimental models to investigate lung cancer biology and anticancer drug response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809028     DOI: 10.1016/s0165-4608(98)00076-4

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines.

Authors:  Alice Pasini; Giulia Paganelli; Anna Tesei; Wainer Zoli; Emanuele Giordano; Daniele Calistri
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

2.  Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.

Authors:  W Zoli; L Ricotti; M Dal Susino; F Barzanti; G L Frassineti; S Folli; A Tesei; F Bacci; D Amadori
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

3.  Correlation analysis between serum neuron-specific enolase and the detection of gene mutations in lung adenocarcinoma.

Authors:  Fang-Zhou Xu; Yan-Bei Zhang
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

4.  Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.

Authors:  Alessandro Passardi; Lorenzo Cecconetto; Monia Dall'agata; Claudio Dazzi; Enzo Pasquini; Giovanni Oliverio; Federica Zumaglini; Wainer Zoli; Oriana Nanni; Carlo Milandri; Giovanni Luca Frassineti; Dino Amadori
Journal:  J Transl Med       Date:  2008-10-31       Impact factor: 5.531

5.  In vitro irradiation system for radiobiological experiments.

Authors:  Anna Tesei; Anna Sarnelli; Chiara Arienti; Enrico Menghi; Laura Medri; Elisa Gabucci; Sara Pignatta; Mirella Falconi; Rosella Silvestrini; Wainer Zoli; Vincenzo D'Errico; Antonino Romeo; Elisabetta Parisi; Rolando Polico
Journal:  Radiat Oncol       Date:  2013-11-01       Impact factor: 3.481

6.  CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells.

Authors:  Alice Zamagni; Alice Pasini; Francesca Pirini; Sara Ravaioli; Emanuele Giordano; Anna Tesei; Daniele Calistri; Paola Ulivi; Francesco Fabbri; Flavia Foca; Angelo Delmonte; Chiara Molinari
Journal:  Int J Oncol       Date:  2020-03-24       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.